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Interrogating the haemodynamic 
effects of haemodialysis 
arteriovenous fistula on cardiac 
structure and function
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Arteriovenous fistula (AVF) is the preferred type of vascular access for maintenance haemodialysis but 
it may contribute to maladaptive cardiovascular remodelling. We studied the effect of AVF creation 
on cardiac structure and function in patients with chronic kidney disease (CKD). In this prospective 
cohort study patients with CKD listed for first AVF creation underwent cardiac magnetic resonance 
(CMR) imaging at baseline and at 6 weeks. All participants had ultrasound measurements of fistula 
blood flow at 6 weeks. The primary outcome was the change in left ventricular (LV) mass. Secondary 
outcomes included changes in LV volumes, LV ejection fraction, cardiac output, LV global longitudinal 
strain and N-terminal-pro B-type natriuretic peptide (NT-proBNP). A total of 55 participants were 
enrolled, of whom 40 (mean age 59 years) had AVF creation and completed both scans. On the second 
CMR scan, a mean increase of 7.4 g (95% CI 1.1–13.7, p = 0.02) was observed in LV mass. Significant 
increases in LV end-diastolic volumes (p = 0.04) and cardiac output (p = 0.02) were also seen after 
AVF creation. No significant changes were observed in LV end-systolic volumes, LV ejection fraction, 
NT-proBNP and LV global longitudinal strain. In participants with fistula blood flows ≥ 600 mL/min 
(n = 22) the mean increase in LV mass was 15.5 g (95% CI 7.3–23.8) compared with a small decrease 
of 2.5 g (95% CI − 10.6 to 5.6) in participants with blood flows < 600 mL/min (n = 18). Creation of AVF 
for haemodialysis resulted in a significant increase of LV myocardial mass within weeks after surgery, 
which was proportional to the fistula flow.
Establishment of a functioning arteriovenous fistula (AVF) has been the mainstay of haemodialysis (HD) treat-
ment due to its durability, delivery of adequate solute clearance and low risk of infection. However, creation of 
an AVF is not benign and may have deleterious effects on cardiac structure and  function1,2. Creation of an AVF 
establishes a shunt from the arterial to the venous circulation, and exposes the low pressure, high capacitance 
venous system to the high pressure, low capacitance arterial system. Immediately following creation, there is an 
associated increase in cardiac output and a decrease in subendocardial perfusion as a consequence of reduced 
systemic vascular resistance, increased myocardial contractility, and an increase in stroke volume and heart  rate3,4. 
Over the following weeks, circulating blood volume increases in conjunction with increases in atrial and brain 
natriuretic  peptides1,5. As the fistula increases in size and blood flow, there are further increases in left ventricular 
(LV) filling pressure and subsequent changes on atrial and ventricular chamber dimensions and  function1,2,5,6. 
The physiological consequences may even progress till there is myocardial decompensation, left ventricle dilata-
tion, and a decline in ejection fraction, eventually leading to LV hypertrophy (LVH) or heart  failure1,7. All these 
changes are additive to underlying pre-existing LVH, dilatation, and dysfunction caused by progressive uraemic 
cardiomyopathy and may be associated with adverse outcomes in dialysis  patients6.
Maladaptive cardiac remodelling and, in particular, increased LV mass is an independent predictor of adverse 
cardiovascular events in CKD and has been used as a surrogate end  point8. In the haemodialysis population, a 
study of adults with no history of congestive heart failure found that each 1 g/m2 increment in LV mass index 
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was associated with a 62% increased risk of fatal and non-fatal cardiovascular  events9. Despite its detrimental 
effects when present, the impact of LVH regression on mortality remains uncertain. An elegant multifactorial 
interventional study by London et al. has demonstrated that a 10% decrease in LV mass translated into a 28% 
decrease in cardiovascular mortality over a 5-year  period10. Foley et al. found that improvements in LV mass 
over a 1-year period after the initiation of dialysis were associated with a reduced likelihood of cardiac failure but 
notably not with mortality  risk11. Patients particularly susceptible to these effects are the ones with pre-existing 
heart disease and high flow fistulas. Fistulas with flows exceeding 2 L/min and upper arm fistulas are traditionally 
at increased risk for the development of heart  failure2,12–14.
The effects of AVF creation on functional and structural cardiac parameters have been previously studied. 
Using cardiac magnetic resonance (CMR) imaging in 24 patients with CKD stage 5 undergoing fistula creation, 
Dundon et al.15 showed a mean increase of 13% in LV mass, 21% in LV end-systolic volumes, and 25% in cardiac 
output 6 months after AVF creation.
Typically, arteriovenous fistulas attain 40–60% of maximum blood flow within 1 day of creation, and reach 
their maximum flow as early as 6 weeks after  creation16. Parallel to the vascular remodelling in the fistula arm, 
creation of a non-physiologic shunt initiates the cascade of haemodynamic changes in the heart muscle, thus, 
perhaps structural changes and LVH develop quickly despite the widely held belief that changes evolve gradually. 
Data show that the mean brachial artery flow increases from 56 mL/min before to 365 mL/min 1 day after and 
to 720 mL/min 28 days after AVF  creation17 and cardiac output increases by 15% in 14  days1.
The aims of this study were two-fold: (i) to investigate myocardial changes early after AVF creation and (ii) 
to determine whether myocardial changes are proportional to the AVF blood flow. To address these questions, a 
prospective study using CMR imaging to evaluate changes on cardiac structure and function 6 weeks after AVF 
surgery in patients with advanced CKD was performed.
Results
Participant characteristics. From December 2, 2016, to August 20, 2018, 252 participants were screened 
and 55 were enrolled (Fig. 1). Of the 197 subjects who were excluded, 131 were found to be ineligible for the 
study. The reasons for exclusion included contraindications to MRI (n = 58), previous AV access surgery (n = 41), 
and frailty (n = 32) (Supplementary Table S1). Of the 49 participants who underwent the first CMR scan, 7 had 
no AVF surgery, and 2 withdrew consent, declining the second scan. In total, 40 participants completed the study 
and were included in the analysis of primary and secondary outcomes. Twenty-two had brachial artery flow 
rates ≥ 600 (1386 ± 785) mL/min and 18 had flows < 600 (266 ± 197) mL/min at 6 weeks (Fig. 1).
The baseline characteristics of the study participants are shown in Table 1. There were no differences between 
the 2 groups in the location of AVF, baseline eGFR, and antihypertensive medication use. Antiplatelet use was 
more common in the higher flow AVF group, and 3 subjects (all in the higher flow group) were started on anti-
platelet therapy post-AVF surgery. The median duration between CMR scans in the higher flow group was 63 days 
(interquartile range 51–115 days) and in the lower flow group was 51 days (interquartile range 46–63 days; 
p = 0.14). Three participants started dialysis within the 6-week period between the two scans (all via central 
venous catheters). The baseline cardiac parameters of the 2 groups were well matched (Supplementary Table S2).
Primary outcome. The primary end point showed a mean increase of 7.4 g (95% CI 1.1–13.7, p = 0.02) in 
LV mass. To adjust for body surface area, change in LV mass index was also calculated. An increase of 5.1 g/m2 
(95% CI 1.6–8.6, p = 0.005) was found.
In the higher flow group the mean increase in LV mass was 15.6 g (95% CI 7.3–23.8) compared with a small 
decrease of 2.5 g (95% CI − 10.6 to 5.6) in the lower flow group (p = 0.003 for comparison; Fig. 2). For the LV 
mass index the mean increase was 9.5 g/m2 (95% CI 5.2–14.0) in the higher flow group compared with a small 
decrease of 0.3 g/m2 (95% CI − 5.2 to 4.6) in the lower flow group (p = 0.003 for comparison; Fig. 2).
Linear regression analyses undertaken showed that increase in the LV mass and LV mass index was more 
pronounced in subjects with higher flow fistulas (Fig. 3) and in subjects with lower LV mass at baseline (Sup-
plementary Fig. S1). In the higher flow group, increase in LV mass was demonstrated in all except 2 subjects.
Secondary outcomes. Table 2 shows the changes observed for other ventricular indexes and atrial size, 
including LV end-diastolic volume, LV end-systolic volume, LV global longitudinal strain, cardiac output, car-
diac index, LA volume, and septal thickness. The mean NT-proBNP levels for all subjects were elevated at base-
line (Table 2) and increased further in the higher flow AVF group (p = 0.05 for comparison; Fig. 4). There was a 
drop in diastolic blood pressure between CMR scans (p = 0.03) but no changes in systolic blood pressure, body 
weight and haematocrit were observed (Table 2).
Discussion
In this prospective observational study we have examined the effect of AVF creation on LV mass in patients 
with advanced CKD using a high fidelity cardiac imaging modality (CMR). There was a substantial increase 
in LV mass observed on the second CMR scan after an average time of 6.3 weeks from AVF surgery. The effect 
was proportional to the brachial artery flow rate, with a 10.2% increase in LV mass in participants with flows 
exceeding 600 mL/min compared with a small decrease in those with lower blood flows. To the best of our 
knowledge this is the first study demonstrating such early changes in LV mass, and linking the early AVF flow 
to the change in LV mass.
Arteriovenous fistula surgery is associated with adaptive cardiac remodelling necessary to accommodate the 
increase in cardiac output sufficient to service the fistula, whilst maintaining systemic blood supply. In a prospec-
tive study of 43 pre-dialysis patients, AVF formation resulted in a sustained reduction in arterial stiffness and 
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blood pressure as well as an increase in cardiac output and LV ejection fraction using  echocardiography18. In 
another prospective echocardiographic study of 47 patients, LV mass increased by 12.2 ± 32% one year post-AV 
access  creation19. With AVF creation, we observed a 4.8% increase in LV mass, 6.1% increase in LV end-diastolic 
volume, 8.7% increase in LA volume and 8.7% increase in cardiac output. In patients with fistula flows ≥ 600 mL/
min, the increases were 10.2%, 8.7%, 14.7% and 13.9%, respectively, and there was also an increase in NT-proBNP 
levels. Linear regression analysis showed that increase in the LV mass and LV mass index was more pronounced 
in subjects with lower LV mass at baseline, and in the higher flow group, increase in LV mass was demonstrated 
in all except 2 subjects. There are no previous studies examining the cardiac changes shortly after AVF creation 
for comparisons of our findings.
The typical blood flow in the brachial artery is approximately 50 mL/min, which rapidly increases 10- to 
20-folds after the fistula is  created17. Upper arm fistulas tend to have the highest blood flow rates and in fact, 
access flow has been shown to be up to twice as high in upper compared with forearm  fistulas2,16. Consequently, 
the incidence of heart failure has been shown to be much higher in patients with a brachiocephalic compared to 
those with a radiocephalic AVF (40 vs 8%)12. In this study, 67% of the upper arm fistulas had flow rates exceeding 
600 mL/min compared with 38% of the forearm fistulas and regression analysis showed that increases in the LV 
mass expectedly were proportional to the brachial artery flow.
Brain natriuretic peptide and its inactive N-terminal fragment have been studied extensively in patients with 
advanced CKD, and both markers have been shown to be strong predictors of cardiovascular morbidity and 
 mortality20,21. They are thought to be secreted in greater quantities in response to increases in myocardial wall 
 stretch22. Population-based studies suggest that plasma levels of brain natriuretic peptide and NT-proBNP are 
useful screening tests for heart failure and asymptomatic LV  dysfunction1,23. In a short-term prospective study 
of 16 CKD patients both atrial natriuretic peptide (ANP) and BNP levels were maximally increased (by 48% and 
68%, respectively) 10 days after AVF  creation1. In another prospective study of 47 patients, plasma NT-proBNP 
levels increased by 170 ± 465% one year post-AV access  creation19. The cardiac structural changes coupled with 
a rise in validated biomarkers of cardiac remodelling, such as NT-proBNP, suggest that observed changes could 
translate into clinical outcomes. To this end, the significant increases in LV and LA volumes in keeping with a 
rise in NT-proBNP in the higher flow AVF group may add important prognostic information. In addition, the 
7 had no AVF creation 
4 patient’s preference for TCVC 
2 kidney transplant 
1 conservative care 
2 declined second CMR  
49 underwent first CMR 
22 AVF flow ≥600 mL/min 
11   0.6-1 L/min 
5    1-2 L/min 
6    >2 L/min 
18 AVF flow <600 mL/min 
11   0.3-0.6 L/min 
7    <0.3 L/min 
252 patients screened 
197 excluded 
131 not fitting inclusion criteria 
     58 contraindications to MRI 
41 previous AV access surgery 
32 frail or co-morbidities      
66 declined to participate 
6 excluded 
4 failed first CMR 
2 withdrew consent 
55 patients consented 
40 had AVF creation and 
completed second CMR 
Figure 1.  Flowchart showing recruitment and arteriovenous fistula (AVF) groups.
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Table 1.  Characteristics of the study participants at baseline. AVF arteriovenous fistula, GFR glomerular 
filtration rate calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula, 
ACEi angiotensin converting enzyme inhibitor,ARB angiotensin II receptor blocker. a Plus-minus values are 
mean ± SD. b Median (IQR). c Current or previous. d Includes 23 non-dialysis participants.
All (n = 40) AVF flow ≥ 600 mL/min (n = 22) AVF flow < 600 mL/min (n = 18) p value
Age, years 59 ±  13a 59 ± 15 60 ± 10 0.80
Female sex, n (%) 19 (48) 9 (41) 10 (56) 0.53
Time between first scan to AVF creation, 
 daysb 9 (4–23) 14 (5–74) 7 (2–17) 0.13
Time between first and second scan,  daysb 58 (47–85) 63 (51–115) 51 (46–63) 0.14
Time between AVF creation to second 
scan,  daysb 44 (41–49) 45 (41–49) 43 (41–46) 0.60
Diabetes mellitus, n (%) 15 (38) 6 (27) 9 (50) 0.19
Hypertension, n (%) 34 (85) 17 (77) 17 (94) 0.20
Ischaemic heart disease, n (%) 7 (18) 5 (23) 2 (11) 0.43
Peripheral vascular disease, n (%) 6 (15) 3 (14) 3 (17) 1.0
Smoking, n (%)c 22 (55) 12 (55) 10 (56) 1.0
Location of AVF, n (%) 0.11
Forearm AVF 16 (40) 6 (27) 10 (56)
Upper arm AVF 24 (60) 16 (73) 8 (44)
Serum creatinine, μmol/Ld 458 ± 127 486 ± 140 394 ± 56 0.14
Estimated GFR, mL/min/1.73  m2d 12 ± 3 11 ± 2 13 ± 3 0.24
Dialysis, n (%) 17 (43) 7 (32) 10 (56) 0.20
Medications, n (%)
ACEi or ARB 13 (33) 6 (27) 7 (39) 0.51
Beta blocker 24 (60) 12 (55) 12 (67) 0.53
Statin 25 (63) 16 (73) 9 (50) 0.19
Aspirin or Clopidogrel 19 (48) 15 (68) 4 (22) 0.005
Figure 2.  Difference in the means of left ventricular (LV) mass (left) and LV mass index (right) between the 
2 scans according to the brachial artery blood flow (p = 0.003 for the difference between groups). This figure 
shows the means in 40 subjects who completed the second cardiac magnetic resonance scan, 22 with blood 
flows ≥ 600 mL/min and 18 with blood flows < 600 mL/min. Change in means and the 95% CI show a significant 
statistical difference between groups (p = 0.003) with an independent t-test.
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minimal changes in LV mass, chamber volumes and NT-proBNP in the lower flow group are physiologically 
plausible and further strengthen our findings.
A recent meta-analysis of 14 studies showed that creation of AVF leads to modest but significant decreases in 
blood pressure in patients with advanced  CKD24, with a preferential reduction in diastolic blood  pressure25. It is 
assumed that the reduction in diastolic blood pressure may have been related to changes in arterial compliance 
and drop in systemic vascular resistance resulting from the complex effects of the fistula-related haemodynamic 
changes. A decrease in diastolic but no significant change in systolic blood pressure was seen in this study cohort. 
Figure 3.  Effect of arteriovenous fistula (AVF) creation based on AVF blood flow. Linear regression analysis 
looking at change in LV mass (above) and LV mass index (below) in study participants with AVF creation. 
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However, this study was powered to observe the change in CMR-derived LV mass and was not specifically pow-
ered to study the changes in blood pressure.
We have demonstrated that AVF creation may increase CMR-derived LV mass in patients with advanced 
CKD, particularly if ‘high flow’. Because of the short interval between the scans (median 8.3 weeks), the increase 
in LV mass observed is unlikely to be resulting from worsening of uraemia, plasma volume overload or changes 
in haematocrit and in fact serum creatinine, body weight and haematocrit did not change significantly between 
the scans. These results demonstrate that AVF creation, which is the cornerstone of haemodialysis treatment, 
has the potential to confer substantial cardiovascular risks in CKD patients, especially the ones with underlying 
cardiovascular disease. However, alternative vascular access choices have their own limitations. First, grafts are 
likely to induce similar haemodynamic changes and so may not reduce cardiovascular maladaptation. Second, 
catheters may have other risks, such as infection, that may result in adverse outcomes. Many unknowns remain, 
and several of those key questions were beyond the scope of this study. For example, baseline NT-proBNP levels, 
LV mass and LV mass index were higher in participants with blood flows < 600 mL/min, which is indicative of 
reduced LV compliance or “diastolic dysfunction”. A plausible alternative explanation of our findings is that 
cardiac stiffening and poor cardiac remodelling in this group resulted in lower AVF blood flows. Appropriately 
designed experimental studies are needed to infer causality. Also the long-term implications of the demonstrated 
changes in LV end-diastolic and LA volumes and BNP are unclear. Further work needs to be done to investigate 
whether they translate into adverse LV  remodelling26 or systolic dysfunction and if so over what time period. 
Or whether they normalise with dialysis.
The strengths of this study include a prospective consecutive design, use of CMR as cardiac imaging modal-
ity, and standardised scanning protocols to limit variability. The study limitations included use of the modified 
Simpson’s method rather than the short axis stack of cines for estimation of LV parameters. We lack power and 
Table 2.  Summary of changes in cardiac magnetic resonance-derived cardiac indexes, clinical and laboratory 
parameters. AVF arteriovenous fistula, LA left atrial, LV left ventricular, BP blood pressure, GFR glomerular 
filtration rate calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula, 
NT-proBNP N-Terminal-pro B-type Natriuretic Peptide, hs-cTnI high-sensitivity cardiac Troponin I. a Plus-
minus values are mean ± SD. b Includes 23 non-dialysis participants.
All (n = 40) AVF flow ≥ 600 mL/min (n = 22) AVF flow < 600 mL/min (n = 18)
Baseline Follow-up p value Baseline Follow-up p value Baseline Follow-up p value
LV mass, g 154.4 ± 52.6a 161.8 ± 50.2 0.02 152.4 ± 55.6a 168.0 ± 55.6 < 0.001 156.9 ± 50.2 154.4 ± 43.0 0.52
LV mass index, 
g/m2 83.7 ± 27.1 88.8 ± 26.2 0.005 80.8 ± 24.7 90.3 ± 24.7 < 0.001 87.3 ± 30.2 87.0 ± 28.6 0.91
LV end-diastolic 
volume, mL 155.8 ± 55.1 165.3 ± 49.6 0.04 167.5 ± 58.7 182.0 ± 54.5 0.03 141.5 ± 48.2 145.0 ± 34.2 0.61
LV end-systolic 
volume, mL 51.3 ± 27.6 55.4 ± 27.1 0.12 57.2 ± 31.7 63.5 ± 32.8 0.10 44.1 ± 20.0 45.5 ± 13.0 0.70
LV ejection frac-
tion, % 67.9 ± 7.8 67.1 ± 7.2 0.52 66.7 ± 8.1 66.1 ± 7.4 0.66 69.2 ± 7.6 68.4 ± 7.0 0.65
LV cardiac 
output, L/min 6.9 ± 2.1 7.5 ± 2.0 0.02 7.2 ± 1.9 8.2 ± 1.9 0.007 6.5 ± 2.2 6.8 ± 1.8 0.61
LV cardiac 




− 15.3 ± 2.3 − 15.7 ± 2.5 0.21 − 15.9 ± 1.9 − 16.0 ± 2.0 0.93 − 14.5 ± 2.6 − 15.2 ± 3.1 0.04
LA volume, mL 85.9 ± 40.1 93.4 ± 34.7 0.10 86.6 ± 43.3 99.3 ± 37.8 0.05 84.9 ± 37.0 86.2 ± 30.1 0.85
LA volume 
index, mL/m2 46.9 ± 21.0 52.1 ± 20.0 0.04 46.6 ± 21.9 54.5 ± 19.9 0.03 47.3 ± 20.6 49.2 ± 20.4 0.59
Septal thickness, 
mm 9.0 ± 2.9 8.5 ± 2.9 0.33 8.5 ± 2.9 7.8 ± 3.0 0.23 9.5 ± 2.9 9.5 ± 2.6 0.90
Body weight, kg 74.7 ± 16.7 73.3 ± 15.2 0.74 75.3 ± 17.2 73.6 ± 15.2 0.76 73.9 ± 16.7 73 ± 15.7 0.89
Systolic BP, 
mmHg 154.3 ± 29.8 147 ± 30.0 0.35 149.8 ± 24.0 146.2 ± 21.1 0.64 160.1 ± 36.3 148.2 ± 39.7 0.43
Diastolic BP, 
mmHg 76.3 ± 13.9 69.4 ± 10.5 0.03 77.3 ± 14.9 70.2 ± 12.2 0.14 74.9 ± 12.9 68.4 ± 8.0 0.13
Hematocrit, % 32.7 ± 5.2 32.4 ± 4.3 0.85 32.0 ± 4.5 31.5 ± 4.0 0.70 33.4 ± 5.9 33.6 ± 4.5 0.93
Serum creati-




11.5 ± 2.6 10.3 ± 4.0 0.25 11.1 ± 2.3 9.5 ± 4.3 0.26 12.6 ± 3.0 11.9 ± 2.6 0.71
NT-proBNP, 
pg/mL 2390 ± 2513 3114 ± 2360 0.08 1647 ± 1401 3174 ± 2439 0.02 2948 ± 3043 3069 ± 2408 0.82
hs-cTnI, pg/mL 13.1 ± 11.2 12.0 ± 9.1 0.36 12.4 ± 12.1 12.7 ± 8.9 0.89 13.7 ± 10.9 11.4 ± 9.6 0.21
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follow-up duration to detect clinically significant outcomes, such as cardiovascular events and patient survival. 
Although the cohort was a single-center experience with relatively small number of participants, our study group 
is representative of the typical CKD population referred for AVF creation. The right heart was not assessed, but 
the study was adequately powered to examine LV mass, which was our primary outcome.
We have shown that AVF creation is associated with a significant increase in LV myocardial mass, cardiac 
chamber dimensions and NT-proBNP levels. The changes are more pronounced in higher blood flow arterio-
venous fistulas. Although these surrogate markers are strongly associated with cardiovascular outcomes, the 
impact of AVF creation on clinical and mortality outcomes remains to be proved.
Methods
Study protocol. A prospective observational single-centre study was conducted between December 2, 
2016, and August 20, 2018. The study protocol (http:// dx. doi. org/ 10. 36399/ gla. pubs. 215112) was approved by 
the institutional review board (North of Scotland Research Ethics Committee reference number, 16/NS/0099) 
and registered with ClinicalTrials.gov (NCT02997046). Written informed consent was obtained from all partici-
pants, and the studies were performed according to hospital guidelines for diagnostic procedures.
Study population. Pre-dialysis and dialysis patients (≥ 18 years of age) listed for creation of an autogenous 
forearm or upper arm AVF were eligible for enrollment. Dialysis patients were only included if they were dialys-
ing via a tunnelled catheter and had no prior permanent access. Consecutive patients with CKD who attended 
the outpatient renal clinics were screened for eligibility. Exclusion criteria were (a) standard contraindications 
to MRI, (b) frail, elderly or participants with multiple or serious comorbidities, and (c) previous arteriovenous 
access creation (autogenous or synthetic graft) in either or both arms. All participants had CMR imaging fol-
lowed by MR angiography with relevance to research questions out with the present  study27.
Study procedures. Baseline CMR imaging was performed (3.0  T Prisma, Magnetom; Siemens Health-
ineers, Erlangen, Germany) before undergoing AVF creation. Repeat CMR and duplex ultrasound (US) of the 
fistula arm was conducted 6 weeks after the creation of AVF.
All scans were performed following a standardised protocol (online Data Supplement, Supplementary Fig. S2). 
Clinical history and blood tests were performed at the time of the first and second CMR scans. Analyses of 
CMR-derived LV mass and chamber volumes was performed offline by a research fellow (A.R.) trained in CMR 
reporting who was blinded to all clinical information and analysed anonymised images in a random order (Sup-
plementary Table S3). The ipsilateral brachial artery flow rate was measured by an interventional radiologist 
with more than 20 years experience in fistula imaging (R.K.) using a Philips iU22 colour duplex scanner (Philips 
Healthcare, Bothell, WA, USA). Participants were categorised into 2 groups based on brachial artery flow rate 
(≥ 600 mL/min vs < 600 mL/min). The threshold of 600 mL/min was used as a surrogate of maturation based on 
the “rule of 6 s” in fistula assessment at 6  weeks28. Brachial artery flows were assessed independently from the 
other cardiac parameters to ensure blinding. Serum N-terminal-pro B-type natriuretic peptide (NT-proBNP) 
and high-sensitivity cardiac Troponin I (hs-cTnI) were measured by immunoassays (Alere NT-proBNP and Stat 
high sensitive Troponin I, Architect, Abbott). Estimated glomerular filtration rate (eGFR) was calculated using 
Figure 4.  Effect of arteriovenous fistula (AVF) creation on N-terminal-pro B-type natriuretic peptide 
(NT-proBNP) levels. Changes in the blood NT-proBNP levels (picograms per millilitre) performed at the 
time of cardiac magnetic resonance scans according to the brachial artery blood flows (≥ 600 mL/min 
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the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)  equation29. Information on the history 
of diabetes mellitus, hypertension, ischaemic heart disease, and peripheral vascular disease was obtained from 
the electronic patient records.
Outcomes. The primary outcome was change in CMR-derived LV mass in the total population. Secondary 
outcome measures included changes in LV end-diastolic and systolic volumes, left atrial (LA) volume, LV ejec-
tion fraction, cardiac output, cardiac index, LV global longitudinal strain, septal thickness, NT-proBNP, and 
hs-cTnI. Primary and secondary outcomes were also assessed for the blood flow subgroups.
Statistical analysis. The sample size was calculated using data from a single-arm pilot study involving 
CMR imaging prior to and 6 months following fistula creation that demonstrated increases in LV mass with AVF 
 creation15. Based on the increase in LV mass as the primary end point, power calculations (including accounting 
for a dropout rate of 15%) indicated that 49 subjects would provide a 7% difference in the LV mass from baseline 
to 6-week CMR with a power of > 80% and a 2-sided α level of 0.05 (online Data Supplement).
Descriptive statistics are expressed as means and standard deviations or medians and interquartile ranges for 
continuous measures as appropriate, and percentages are reported for categorical variables. We used independent 
sample t-tests and Pearson’s chi-squared tests to explore differences in baseline characteristics.
Independent t-tests were also used to compare the change in LV mass between the first and second scans for 
the total population and between the 2 groups. Two-sided tests were performed for all analyses, and the level of 
significance was set at p < 0.05. To estimate pre- versus post-AVF creation differences, the change between initial 
and subsequent measurements was calculated for each person. The mean change was compared between the 
2 groups with an unpaired t-test. For comparisons of non-normally distributed data, Wilcoxon rank-sum and 
Wilcoxon signed rank tests were used. All statistical analyses were conducted with Stata/SE Statistical Software, 
version 15.0 (StataCorp, College Station, Tex).
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